Prospera™ Liver

Built to surveil. Trusted to protect.

The newest evolution of Prospera™ is officially here.

We are proud to introduce Prospera™ Liver, marking a significant milestone as the first donor-derived cell-free DNA (dd-cfDNA) test commercially available for liver transplant recipients.

Built on the same industry-leading Prospera™ technology already trusted for kidney, heart, and lung patients, this new evolution brings our proven precision and advanced insights to liver transplant care.

How Prospera™ works

With a simple blood test Prospera™ evaluates the level of donor-derived cell-free DNA (dd-cfDNA) in a transplant patient’s blood to identify early signs of organ injury or rejection.^1-3

PRO_L_WB_BA_Liver_20260709_NAT-8024349_Chart

Prospera™ Liver uses a donor fraction threshold of ≥10% to indicate active rejection.⁴

dd-cfDNA fraction trends for ongoing surveillance of your patient’s long-term health.

Chronological tracking of test results and risk to assist in care decisions.

Download the new Prospera™ Liver Clinician's guide to results

Download the Prospera™ Liver sample reports

Early insight means early action–and a better chance to protect the life a transplant makes possible

This deeper insight may help physicians:

PRO_L_WB_BA_Liver_20260708_NAT-8024349-04

Reduce the need for surveillance biopsies

PRO_L_WB_BA_Liver_20260708_NAT-8024349-05

Monitor changes in graft health over time

PRO_L_WB_BA_Liver_20260708_NAT-8024349-06

Focus attention where intervention may matter most

Find out more about Prospera™ for liver transplant recipients

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Sigdel TK, et al. Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR. J Clin Med. 2018;8(1):19.

²Kim PJ, Olympios M, Siu A, et al. A novel donor-derived cell-free DNA assay for the detection of acute rejection in heart transplantation. J Heart Lung Transplant. 2022;41(7):919-927. doi:10.1016/j.healun.2022.04.002.

³Rosenheck JP, Ross DJ, Botros M, et al. Clinical Validation of a Plasma Donor-derived Cell-free DNA Assay to Detect Allograft Rejection and Injury in Lung Transplant. Transplantation Direct. 2022;8(4). doi:10.1097/txd.0000000000001317.

⁴Internal clinical validation data demonstrating the use of donor-derived cell-free DNA (dd-cfDNA) for the detection of liver allograft rejection has been submitted for publication.

For additional performance data, please call us at 650-273-4468 #3